“Eating” Cancer cells by blocking CD47 signaling: Cancer therapy by targeting the innate immune checkpoint
Differing from the adaptive immune checkpoint mediated by programmed cell death-1 (PD-1) PD-1-ligand or CTLA-4, the CD47 and signal regulatory protein α (SIRPα) axis is emerging as a novel innate immune checkpoint of the immune cells of myeloid lineage. A balance should be established between the du...
Main Authors: | Yi-Rong Xiang, Li Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | Cancer Translational Medicine |
Subjects: | |
Online Access: | http://www.cancertm.com/article.asp?issn=2395-3977;year=2017;volume=3;issue=6;spage=200;epage=208;aulast=Xiang |
Similar Items
-
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
by: Yan Yang, et al.
Published: (2021-07-01) -
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer
by: Oscar Arrieta, et al.
Published: (2020-04-01) -
Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy
by: Lian S, et al.
Published: (2019-11-01) -
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
by: Tracy C. Kuo, et al.
Published: (2020-11-01)